CYP1A2 often interacts with other cytochrome P450 enzymes, which can lead to complex drug-drug interactions. For example, medications that inhibit CYP1A2 can lead to increased plasma levels of drugs metabolized by this enzyme, while inducers can decrease their levels. This interplay necessitates careful consideration in polypharmacy, especially in individuals with multiple comorbidities.
